Published works by Caitlin M. Wilmot

Published works

• A Heightened Bar: Federal Circuit Leaves Functional Antibody Claims on Thin Ice

  Biosimilars Law Bulletin · February 24, 2021

  LEX-WK-Z9WAQ117
• Amgen Faces “Uphill Battle” in Defending Antibody Genus Patentability

  Biosimilars Law Bulletin · February 11, 2021

  LEX-WK-PCNZPM8A
• Big Pharma to Face Off at Federal Circuit Oral Arguments Over Antibody Genus Patentability

  Biosimilars Law Bulletin · November 24, 2020

  LEX-WK-YMFA501B
• Federal Circuit Refuses to Reconsider Its Panel Decision Finding No Common Ownership of Immunex’s Enbrel Patents

  Biosimilars Law Bulletin · October 6, 2020

  LEX-WK-G8X6Y1D2
• Eli Lilly Files PGR Petition against Genentech’s IL-17A/F Heterodimer Patent

  Biosimilars Law Bulletin · April 17, 2019

  LEX-WK-1PSR60GV
• USPTO Celebrates Women in Innovation and Renames Auditorium in Honor of Clara Barton

  PTAB Law Blog · March 6, 2019

  LEX-WK-T90SE739
• FDA Issues New Guidance on Biosimilar Development under the BPCIA

  Biosimilars Law Bulletin · January 11, 2019

  LEX-WK-RS099Z08
• Amendments on Amendments: USPTO Proposes Changes to the Motion to Amend Practice in AIA Trials

  PTAB Law Blog · November 12, 2018

  LEX-WK-EWNFVGHZ
• Third Time’s a Charm? Amgen Files Another BPCIA Lawsuit Against Apotex

  Biosimilars Law Bulletin · August 30, 2018

  LEX-WK-4F32EJ9N
• Voluntary Dismissal Without Prejudice Does Not Nullify § 315(b)’s Time Bar

  PTAB Law Blog · August 22, 2018

  LEX-WK-NN1XKXM6
• PTAB Denies Sandoz’s IPR Petition for Humira®-Related Patent

  Biosimilars Law Bulletin · May 17, 2018

  LEX-WK-RTWEBKWD
• USPTO Proposes Narrower AIA Claim Construction Standard to Match District Courts

  PTAB Law Blog · May 14, 2018

  LEX-WK-KPBVAJP0
• Global Approvals for Insulin Glargine Promise a More Affordable, Long-Acting Treatment for Diabetes

  Biosimilars Law Bulletin · April 3, 2018

  LEX-WK-MSMH5CTG
• Patent Examiners Will Get a Head Start with Automated Prior Art Searches

  PTAB Law Blog · March 29, 2018

  LEX-WK-XCH0ER7C
• Lupin’s Generic Version of Tamiflu® Joins the Band of Flu Fighters

  Biosimilars Law Bulletin · February 20, 2018

  LEX-WK-4AS7C8S8
• USPTO Trims the Regulatory Fat

  PTAB Law Blog · January 25, 2018

  LEX-WK-0ZZ3KQC5
• Federal Biosimilars Act Preempts State Law

  Biosimilars Law Bulletin · January 2, 2018

  LEX-WK-FWCSZES1
• PTAB Issues Guidance on Motions to Amend in View of <i>Aqua Products</i>

  PTAB Law Blog · December 11, 2017

  LEX-WK-WVWTBGKQ
• Humira®’s Wall of Patents Continues to Come Under Attack

  Biosimilars Law Bulletin · November 13, 2017

  LEX-WK-T6QWBARA
• How Many References Is Too Many for Challenging a Patent on Obviousness?

  PTAB Law Blog · April 10, 2017

  LEX-WK-KZFDHTMX
• PTAB’s Discretion to Deny Institution under 35 U.S.C. § 325(d)

  PTAB Law Blog · October 13, 2016

  LEX-WK-JJSKZTVE
• Overburdened: Federal Circuit Reverses Based On PTAB’s Improper Shifting Of Burden To Patent Owner

  PTAB Law Blog · August 5, 2016

  LEX-WK-KHHC7MY1